Qin-Fu Feng

List of Publications by Year
in descending order

56	772	623574	642610
papers	citations	14 h-index	23 g-index

59	59	59	855
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Nonâ€“Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy. JAMA Oncology, 2021, 7, 1178.	3.4	128
2	Risk Factors for Brain Metastases in Locally Advanced Non-Small Cell Lung Cancer With Definitive Chest Radiation. International Journal of Radiation Oncology Biology Physics, 2014, 89, 330-337.	0.4	59
3	A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1565-1573.	0.5	32
4	Postoperative radiotherapy for completely resected Masaoka stage III thymoma: a retrospective study of 65 cases from a single institution. Radiation Oncology, 2013, 8, 199.	1.2	30
5	Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy. Oncologist, 2016, 21, 1530-1537.	1.9	30
6	Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy. Annals of Surgical Oncology, 2019, 26, 2890-2898.	0.7	28
7	Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma. BMC Cancer, 2020, 20, 144.	1.1	28
8	A Single-Center Analysis of the Treatment and Prognosis of Patients With Thymic Carcinoma. Annals of Thoracic Surgery, 2017, 104, 1718-1724.	0.7	25
9	Patterns and predictors of recurrence after radical resection of thymoma. Radiotherapy and Oncology, 2015, 115, 30-34.	0.3	23
10	Postoperative Radiotherapy in Pathological T2â€“3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. Oncologist, 2020, 25, e701-e708.	1.9	23
11	Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. Radiation Oncology, 2019, 14, 106.	1.2	22
12	A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. Radiation Oncology, 2019, 14, 48.	1.2	20
13	Histological subtypes of lung cancer in Chinese women from 2000 to 2012. Thoracic Cancer, 2014, 5, 447-454.	0.8	17
14	Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Nonâ€“Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants. JAMA Network Open, 2019, 2, e1918070.	2.8	17
15	Clinical outcomes and radiation pneumonitis after concurrent <scp>EGFR</scp>â€tyrosine kinase inhibitors and radiotherapy for unresectable stage <scp>III</scp> nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 814-823.	0.8	17
16	A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. Radiotherapy and Oncology, 2019, 140, 159-166.	0.3	16
17	Ultrasound-guided intraoperative electron beam radiation therapy: A phantom study. Physica Medica, 2020, 78, 1-7.	0.4	16
18	Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIBâ€“III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial. Oncologist, 2021, 26, e2151-e2160.	1.9	15

#	Article	IF	Citations
19	Tobacco smoking and trends in histological subtypes of female lung cancer at the Cancer Hospital of the Chinese Academy of Medical Sciences over 13â€‰years. Thoracic Cancer, 2019, 10, 1717-1724.	0.8	14
20	Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. Acta OncolÃ³gica, 2021, 60, 627-634.	0.8	13
21	Nomogram and recursive partitioning analysis to predict overall survival in patients with stage IIB-III thoracic esophageal squamous cell carcinoma after esophagectomy. Oncotarget, 2016, 7, 55211-55221.	0.8	13
22	Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer. Radiation Oncology, 2017, 12, 195.	1.2	12
23	Expertsâ€™ consensus on intraoperative radiotherapy for pancreatic cancer. Cancer Letters, 2019, 449, 1-7.	3.2	12
24	The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases. Journal of Cancer, 2019, 10, 1985-1990.	1.2	11
25	A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis. Oncotarget, 2017, 8, 41102-41112.	0.8	10
26	Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese twoâ€‐center study. Thoracic Cancer, 2019, 10, 1431-1440.	0.8	10
27	A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma. BMC Cancer, 2020, 20, 130.	1.1	10
28	S-1â€“Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial. Frontiers in Oncology, 2020, 10, 1499.	1.3	9
29	A feasible study on using multiplexed sensitivity-encoding to reduce geometric distortion in diffusion-weighted echo planar imaging. Magnetic Resonance Imaging, 2018, 54, 153-159.	1.0	8
30	A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. BMC Cancer, 2020, 20, 901.	1.1	7
31	Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial. BMC Cancer, 2020, 20, 278.	1.1	7
32	A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced nonâ€‐small cell lung cancer. Radiotherapy and Oncology, 2021, 156, 244-250.	0.3	7
33	The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC). Oncotarget, 2017, 8, 48922-48929.	0.8	7
34	Adenoid Cystic Carcinoma of Lobar Bronchial Origin: 20-Year Experience at a Single Institution. Annals of Surgical Oncology, 2022, 29, 4408-4416.	0.7	7
35	Myasthenia Gravis Is Not an Independent Prognostic Factor of Thymoma: Results of a Propensity Score Matching Trial of 470 Patients. Frontiers in Oncology, 2020, 10, 583489.	1.3	6
36	Role of modern neoadjuvant chemoradiotherapy in locally advanced thymic epithelial neoplasms. Tumori, 2020, 107, 030089162096798.	0.6	6

#	Article	IF	Citations
37	CHST15 promotes the proliferation of TEâ€'1 cells via multiple pathways in esophageal cancer. Oncology Reports, 2020, 43, 75-86.	1.2	6
38	Treatment outcomes of patients with stage <scp>III nonâ€"small cell lung cancer</scp> and interstitial lung diseases receiving intensityâ€modulated radiation therapy: A singleâ€center experience of 85 cases. Thoracic Cancer, 2022, , .	0.8	5
39	Impact of thoracic radiation therapy after chemotherapy on survival in extensiveâ€stage small cell lung cancer: A propensity scoreâ€matched analysis. Thoracic Cancer, 2019, 10, 799-806.	0.8	4
40	Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection: A Propensity Score-Matched Analysis. Annals of Surgical Oncology, 2021, 28, 7076-7086.	0.7	4
41	Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity scoreâ€matched analysis. Thoracic Cancer, 2021, 12, 1831-1840.	0.8	4
42	Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases. Lung Cancer, 2021, 157, 116-123.	0.9	4
43	A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis. Frontiers in Oncology, 2021, 11, 781340.	1.3	4
44	Chemoradiotherapy is an alternative choice for patients with primary mediastinal seminoma. Radiation Oncology, 2022, 17, 58.	1.2	4
45	Development and validation of a prediction model using molecular marker for longâ€term survival in unresectable stage <scp>III</scp> nonâ€small cell lung cancer treated with chemoradiotherapy. Thoracic Cancer, 2022, 13, 296-307.	0.8	4
46	Debulking Surgery Plus Radiation: Treatment Choice for Unresectable Stage III Thymic Carcinoma. Thoracic and Cardiovascular Surgeon, 2020, 68, 440-445.	0.4	3
47	Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110619.	1.4	3
48	Primary intrathoracic liposarcoma: a clinical analysis of 31 cases. Cancer Communications, 2019, 39, 1-3.	3.7	2
49	Sclerosing thymoma: a case report and literature review. Translational Cancer Research, 2020, 9, 3034-3039.	0.4	2
50	Longâ€term outcomes of intraoperative radiotherapy forÂearlyâ€stage breast cancer in China: a multicenter realâ€worldÂstudy. Cancer Communications, 2022, 42, 277-280.	3.7	2
51	Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer. Clinical Medicine Insights: Oncology, 2022, 16, 117955492210803.	0.6	2
52	Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: An Automatic Treatment Planning Study . Cancer Management and Research, 2020, Volume 12, 9643-9653.	0.9	1
53	Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol. BMC Cancer, 2020, 20, 877.	1.1	1
54	Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis. Frontiers in Oncology, 2021, 11, 618776.	1.3	1

#	Article	IF	Citations
55	The Time-series Behavior of Systemic Inflammation-immune Status in Predicting Survival of Locally Advanced Non-small Cell Lung Cancer Treated with Chemoradiotherapy. Journal of the National Cancer Center, 2021, , .	3.0	1
56	ASO Author Reflections: Surgery With or Without Additional Radiotherapy as a Therapeutic Strategy in ACC of Lobar Bronchial Origin. Annals of Surgical Oncology, 2022, , 1.	0.7	0